Headline–confidence gap
Headline confirmed
Management confidence reinforces the reported beat.
MDT · Q2 2026
Medtronic plc
51EarnIQ signal
↗
Confidence rising
Mild quarter-over-quarter shiftMedtronic delivered its strongest revenue growth in a decade, backed by robust cardiac ablation momentum and confident FY27 guidance.
- ✓Guidance was none, with high specificity.
- ✓Management tone registered as confident (88/100).
- ✓EarnIQ detected 0 potential management deflections.
EPS: reported vs expected—— vs —
Revenue: reported vs expected—— vs —
Guidance specificityHighChange not comparable
Market expectations are being matched to this report.
Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor.
Premium intelligence
The evidence behind the signal
Management language
Why confidence moved
“Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor.”
“As we look to FY27, we are entering the year with strong momentum, a resilient operating foundation, and a clear path to deliver durable growth.”
“These results represent the compounding impact of deliberate choices we’ve made to strengthen our strategy, sharpen execution, and invest in the areas that will drive our future.”
Guidance specificity
90/100
High specificity
Medtronic guided to FY27 organic revenue growth of 6.75% to 7.25% and diluted non-GAAP EPS in the range of $5.90 to $6.00.
Pressure point
Tariff impacts affecting operating margins
0 potential deflections detected in management communication.
Narrative break
What changed
Active acceleration of tuck-in M&A and venture capital transactions including CathWorks, Scientia Vascular, SPR Therapeutics, and Pulnovo Medical.
Q&A evidence
Management responses
No material Q&A deflections were detected.
Key positives
- Delivered the highest annual revenue growth in 10 years, with FY26 revenue of $36.4 billion up 5.8% organic.
- Cardiac Ablation Solutions revenue surged 78% globally, including 124% U.S. growth and 8 points of U.S. share gain.
- Robust cash flow generation with $7.3 billion in cash from operations and $5.4 billion in free cash flow.
Key risks
- Tariff impacts affecting operating margins, with a stated 80 basis points impact in Q4 and 50 basis points for the full year.
- Foreign currency exchange volatility and its impact on non-GAAP diluted EPS.
- Competitive pressures in high-growth segments requiring continuous pipeline and M&A execution.
Topic velocity
Language versus prior quarter
M&ANew
CostNew
ChinaNew
MarginNew
RecordNew
iPhoneNew
Signal composition
What drove the EarnIQ score
Tone+20
Eps Beat+0
Guidance+15
New Signal+8
Miss Penalty+0
Qoq Improvement+8
Deflection Penalty+0